Jpmorgan Chase & CO Nurix Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 36,796 shares of NRIX stock, worth $921,371. This represents 0.0% of its overall portfolio holdings.

Number of Shares

36,796

Previous 34,324 7.2%

Holding current value

$921,371

Previous $504,000 52.18%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$12.02 - $21.3 $29,713 - $52,653	2,472 Added 7.2%	36,796 $767,000
Q1 2024 May 10, 2024	SELL	$7.77 - $15.66 $106,184 - $214,009	-13,666 Reduced 28.48%	34,324 $504,000
Q4 2023 Feb 12, 2024	SELL	$4.25 - $10.71 $20,829 - $52,489	-4,901 Reduced 9.27%	47,990 $495,000
Q3 2023 Nov 14, 2023	BUY	$7.86 - $10.08 $503 - $645	64 Added 0.12%	52,891 $415,000
Q2 2023 Aug 11, 2023	BUY	$8.7 - $13.28 $148,700 - $226,981	17,092 Added 47.83%	52,827 $527,000
Q1 2023 May 18, 2023	BUY	$8.56 - $13.26 $304,265 - $471,326	35,545 Added 18707.89%	35,735 $317,000
Q1 2023 May 11, 2023	SELL	$8.56 - $13.26 $761,035 - $1.18 Million	-88,906 Reduced 99.79%	190 $1,000
Q4 2022 Feb 13, 2023	BUY	$9.86 - $14.59 $599,704 - $887,392	60,822 Added 215.12%	89,096 $979,000
Q3 2022 Nov 14, 2022	SELL	$12.33 - $19.81 $1.25 Million - $2.01 Million	-101,251 Reduced 78.17%	28,274 $368,000
Q2 2022 Aug 11, 2022	BUY	$7.88 - $14.82 $70,990 - $133,513	9,009 Added 7.48%	129,525 $1.64 Million
Q1 2022 May 11, 2022	BUY	$12.94 - $29.65 $396,792 - $909,187	30,664 Added 34.13%	120,516 $1.69 Million
Q4 2021 Feb 10, 2022	BUY	$26.43 - $34.5 $842,244 - $1.1 Million	31,867 Added 54.96%	89,852 $2.6 Million
Q3 2021 Nov 12, 2021	BUY	$22.71 - $36.69 $1.32 Million - $2.13 Million	57,985 New	57,985 $1.74 Million

Others Institutions Holding NRIX

# of Institutions

184

Shares Held

66.3M

Call Options Held

40.9K

Put Options Held

106K

View Full List

About Nurix Therapeutics, Inc.

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.18B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

More about NRIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Nurix Therapeutics, Inc. Transaction History